SMYD3
Overview
SMYD3 encodes a histone methyltransferase (SET and MYND domain-containing protein 3) that trimethylates histone H4K20 and H3K4, promoting transcriptional activation. In GBM, SMYD3 has been identified as a focal deletion target, suggesting a potential tumor-suppressive context.
Alterations observed in the corpus
- Single-gene focal deletion target in GBM; identified alongside LRP1B, NPAS3, and LSAMP as single-gene focal deletion events in the TCGA GBM comprehensive genomic characterization PMID:24120142
Cancer types (linked)
- GBM — focal deletion target identified in the TCGA GBM comprehensive genomic characterization PMID:24120142
Co-occurrence and mutual exclusivity
- Co-identified as a single-gene focal deletion target in the same GBM dataset as LRP1B, NPAS3, and LSAMP PMID:24120142
Therapeutic relevance
- No direct therapeutic targeting reported in the corpus.
Open questions
- Functional significance of SMYD3 focal deletion in GBM is not established; SMYD3 is paradoxically reported as an oncogene in other tumor types (e.g., colorectal, hepatocellular), making its role in GBM as a deletion target noteworthy and unresolved.
Sources
This page was processed by crosslinker on 2026-05-09.